Standardized diagnostic criteria, risk-adapted therapies, and molecularly informed management became the backbone of hematology practice across polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, and myelodysplastic syndromes, driving guideline adoption, harmonized trial designs, and education.